Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 8/20 | 0.65 |
| ▸ | KDR | P35968 | 11/20 | 0.62 |
| ▸ | RAF1 | P04049 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19564942 | 0.84 | BRAF (0.59) | BRAFKDRRAF1 | |
| SCHEMBL17522961 | 0.81 | BRAF (0.66) | BRAFKDRRAF1 | |
| SCHEMBL4458171 | 0.79 | BRAF (1.00) | BRAFKDR | |
| SCHEMBL4463079 | 0.78 | BRAF (1.00) | BRAFKDR | |
| SCHEMBL2936061 | 0.77 | KDR (0.69) | BRAFKDRRAF1 | |
| SCHEMBL3062270 | 0.77 | BRAF (1.00) | BRAFKDR | |
| SCHEMBL3766226 | 0.77 | RAF1 (0.68) | BRAFKDRRAF1 | |
| SCHEMBL17179270 | 0.76 | KDR (1.00) | BRAFKDR | |
| SCHEMBL17179251 | 0.76 | KDR (1.00) | BRAFKDR | |
| SCHEMBL4472974 | 0.76 | BRAF (1.00) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951041-B2 | Crystalline C21H22Cl2N4O2 malonate | BIOMED VALLEY DISCOVERIES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170320850-A1 | CRYSTALLINE C21H22Cl2N4O2 MALONATE | ALBANY MOLECULAR RESEARCH, INC. | 2017-11-09 | — | — | US | disclosed |
| US-9676746-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9670177-B2 | Crystalline C21H22Cl2N4O2 malonate | BIOMED VALLEY DISCOVERIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170095575-A1 | COMBINATION THERAPIES USING AGENTS THAT TARGET TUMOR-ASSOCIATED STROMA OR TUMOR CELLS AND OTHER PATHWAYS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20160317517-A1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. | 2016-11-03 | — | — | US | disclosed |
| US-20160310476-A1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. | 2016-10-27 | — | — | US | disclosed |
| US-20160221987-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160221988-A1 | CRYSTALLINE C21H22Cl2N4O2 MALONATE | BIOMED VALLEY DISCOVERIES, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160045556-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045556-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | MKI67, HCCS, NCF1 | BRAF 147/4885KDR 2680/4885RAF1 849/4885 |
| US-20160310476-A1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BRAF, RAF1, MAPK3 | BRAF 1/4885KDR 197/4885RAF1 2/4885 |
| US-20160221988-A1 | CRYSTALLINE C21H22Cl2N4O2 MALONATE | MAL2, ME1, SLC22A11 | BRAF 1869/4885KDR 3429/4885RAF1 1985/4885 |
| US-20170095575-A1 | COMBINATION THERAPIES USING AGENTS THAT TARGET TUMOR-ASSOCIATED STROMA OR TUMOR CELLS AND OTHER PATHWAYS | IGLV6-57, IGSF11, TNFRSF9 | BRAF 2156/4885KDR 31/4885RAF1 3458/4885 |
| US-20160317517-A1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | KRAS, BRAF, NRAS | BRAF 2/4885KDR 281/4885RAF1 16/4885 |
| US-20160221987-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | BRAF 1621/4885KDR 2926/4885RAF1 2308/4885 |
| US-20170320850-A1 | CRYSTALLINE C21H22Cl2N4O2 MALONATE | MAL2, ME1, SLC22A11 | BRAF 1869/4885KDR 3429/4885RAF1 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.